journal article·2023-02-28Open access

A Molecular Docking Study Reveals That Short Peptides Induce Conformational Changes in the Structure of Human Tubulin Isotypes αβI, αβII, αβIII and αβIV

Oluwakemi Ebenezer, Nkululeko Damoyi, Michael Shapi, Gane Ka-Shu Wong, Jack A. Tuszynski

Abstract

Microtubules are cylindrical protein polymers assembled in the cytoplasm of all eukaryotic cells by polymerization of aβ tubulin dimers, which are involved in cell division, migration, signaling, and intracellular traffic. These functions make them essential in the proliferation of cancerous cells and metastases. Tubulin has been the molecular target of many anticancer drugs because of its crucial role in the cell proliferation process. By developing drug resistance, tumor cells severely limit the successful outcomes of cancer chemotherapy. Hence, overcoming drug resistance motivates the design of new anticancer therapeutics. Here, we retrieve short peptides obtained from the data repository of antimicrobial peptides (DRAMP) and report on the computational screening of their predicted tertiary structures for the ability to inhibit tubulin polymerization using multiple combinatorial docking programs, namely PATCHDOCK, FIREDOCK, and ClusPro. The interaction visualizations show that all the best peptides from the docking analysis bind to the interface residues of the tubulin isoforms αβl, αβll, αβlll, and αβlV, respectively. The docking studies were further confirmed by a molecular dynamics simulation, in which the computed root-mean-square deviation (RMSD), and root-mean-square fluctuation (RMSF), verified the stable nature of the peptide–tubulin complexes. Physiochemical toxicity and allergenicity studies were also performed. This present study suggests that these identified anticancer peptide molecules might destabilize the tubulin polymerization process and hence can be suitable candidates for novel drug development. It is concluded that wet-lab experiments are needed to validate these findings.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Biochemical and Structural Characterization · Microbial Natural Products and Biosynthesis · Chemical Synthesis and Analysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry, Faculty of Natural Science, Mangosuthu University of Technology, Umlazi 4031, South Africa

Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada

Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB T6G 2E1, Canada

Department of Physics, University of Alberta, Edmonton, AB T6G 2E1, Canada

Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada

Department of Mechanical and Aerospace Engineering, (DIMEAS), Politecnico di Torino, 10129 Turin, Italy

Funding

NSERC (Canada)

References (43)

Show source-provided references
1. Dietary flavonoid fisetin binds to β-tubulin and disrupts microtubule dynamics in prostate cancer cells10.1016/j.canlet.2015.07.030 ↗
2. Ebenezer, O., Shapi, M., and Tuszynski, J.A. (2022). A Review of the Recent Developments of Molecular Hybrids Targeting Tubulin Polymerization. Int. J. Mol. Sci., 23.10.3390/ijms23074001 ↗
3. The roles of beta-tubulin mutations and isotype expression in acquired drug resistance10.1177/117693510700300028 ↗
4. The tubulin colchicine domain: A molecular modeling perspective10.1002/cmdc.201100361 ↗
5. Multiple forms of tubulin: Different gene products and covalent modifications
6. Interaction of desacetamidocolchicine, a fast binding analogue of colchicine with isotypically pure tubulin dimers alpha beta II, alpha beta III, and alpha beta IV10.1016/S0021-9258(17)34064-4 ↗
7. Microtubule dynamics in vitro are regulated by the tubulin isotype composition10.1073/pnas.91.24.11358 ↗
8. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes10.1021/bi962724m ↗
9. Plant-Derived Bioactive Peptides: A Treatment to Cure Diabetes10.1007/s10989-019-09899-z ↗
10. Potential of plant-derived peptides for the improvement of memory and cognitive function10.1016/j.peptides.2021.170571 ↗
11. In silico design of tubulin-targeted antimitotic peptides10.1038/nchem.401 ↗
12. Kumbhar, B.V., Borogaon, A., Panda, D., and Kunwar, A. (2016). Exploring the Origin of Differential Binding Affinities of Human Tubulin Isotypes αβII, αβIII and αβIV for DAMA-Colchicine Using Homology Modelling, Molecular Docking and Molecular Dynamics Simulations. PLoS ONE, 11.10.1371/journal.pone.0156048 ↗
13. Kinetics of colchicine binding to purified beta-tubulin isotypes from bovine brain10.1016/S0021-9258(18)42215-6 ↗
14. Kumbhar, B.V., Panda, D., and Kunwar, A. (2018). Interaction of microtubule depolymerizing agent indanocine with different human αβ tubulin isotypes. PLoS ONE, 13.10.1371/journal.pone.0194934 ↗
15. DRAMP 3.0: An enhanced comprehensive data repository of antimicrobial peptides10.1093/nar/gkab651 ↗
16. Improved PEP-FOLD Approach for Peptide and Miniprotein Structure Prediction10.1021/ct500592m ↗
17. Antiviral peptides against the main protease of SARS-CoV-2: A molecular docking and dynamics study10.1016/j.arabjc.2021.103315 ↗
18. AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR10.1007/BF00228148 ↗
19. SWISS-MODEL: Homology modelling of protein structures and complexes10.1093/nar/gky427 ↗
20. A method to identify protein sequences that fold into a known three-dimensional structure10.1126/science.1853201 ↗
21. Verification of protein structures: Patterns of nonbonded atomic interactions10.1002/pro.5560020916 ↗
22. Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments10.1007/s10822-013-9644-8 ↗
23. Duhovny, D., Nussinov, R., and Wolfson, H.J. (2002). International Workshop on Algorithms in Bioinformatics, Springer.
24. The ClusPro web server for protein-protein docking10.1038/nprot.2016.169 ↗
25. FireDock: A web server for fast interaction refinement in molecular docking10.1093/nar/gkn186 ↗
26. Bowers, K.J., Chow, D.E., Xu, H., Dror, R.O., Eastwood, M.P., Gregersen, B.A., Klepeis, J.L., Kolossvary, I., Moraes, M.A., and Sacerdoti, F.D. (2006, January 11–17). Scalable algorithms for molecular dynamics simulations on commodity clusters. Proceedings of the SC’06: Proceedings of the 2006 ACM/IEEE Conference on Supercomputing, Tampa, FL, USA.10.1145/1188455.1188544 ↗
27. Modeling Local Structural Rearrangements Using FEP/REST: Application to Relative Binding Affinity Predictions of CDK2 Inhibitors10.1021/ct300911a ↗
28. Protein identification and analysis tools in the ExPASy server
29. AllerTOP v.2—A server for in silico prediction of allergens10.1007/s00894-014-2278-5 ↗
30. Homology modeling and virtual screening approaches to identify potent inhibitors of VEB-1 β-lactamase10.1186/1742-4682-10-22 ↗
31. Molecular dynamics simulations of tubulin structure and calculations of electrostatic properties of microtubules10.1016/j.mcm.2005.05.002 ↗
32. A simple method for displaying the hydropathic character of a protein10.1016/0022-2836(82)90515-0 ↗
33. In silico design of peptide inhibitors of tubulin: Amyloid-β as a lead compound10.1080/07391102.2020.1745691 ↗
34. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities10.1517/17460441.2015.1032936 ↗
35. Discovery, structure, function, and applications of cyclotides: Circular proteins from plants10.1093/jxb/erw210 ↗
36. Cyclotides as a basis for drug design10.1517/17460441.2012.661554 ↗
37. Henriques, S.T., and Craik, D.J. (2015). Discovery of peptide drugs from natural sources. Pept. Chem. Drug Des., 203–245.10.1002/9781118995303.ch6 ↗
38. Cyclotides: From Structure to Function10.1021/acs.chemrev.9b00402 ↗
39. On the effect of a polypeptide isolated from “Kalata-Kalata” (Oldenlandia affinis DC) on the oestrogen dominated uterus10.1111/j.1600-0773.1973.tb01541.x ↗
40. Circulins A and B. Novel human immunodeficiency virus (HIV)-inhibitory macrocyclic peptides from the tropical tree Chassalia parvifolia10.1021/ja00099a064 ↗
41. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?10.1016/S1470-2045(08)70029-9 ↗
42. Immunosuppressive peptides and their therapeutic applications10.1016/j.drudis.2013.12.002 ↗
43. The future of peptide-based drugs10.1111/cbdd.12055 ↗